Priolo Manuela
Operative Unit of Medical Genetics and Laboratory of Genetics, AORN A Cardarelli, Naples, Italy
-related Malan syndrome (MALNS) is characterized by prenatal and postnatal overgrowth, macrocephaly, advanced bone age and/or skeletal anomalies (scoliosis, pes planus), slender body habitus, developmental delay / intellectual disability (typically in the moderate-to-severe range), behavioral problems (including a specific anxious profile and attention-deficit/hyperactivity disorder [ADHD]), and ocular findings (most commonly strabismus, refractive errors, and blue sclerae). Affected individuals typically have distinctive facial features, including a long and triangular face, high anterior hair line with prominent forehead, depressed nasal bridge, deep-set eyes, downslanted palpebral fissures, short nose with anteverted nares and upturned tip, long philtrum, small mouth that is often held open, thin vermilion of the upper lip, an everted lower lip, and a prominent chin. Other findings may include autonomic signs (episodic ataxia with dizziness and nausea and/or postural fainting), seizures or EEG abnormalities, hypotonia, dental anomalies, long bone fractures, and (rarely) congenital heart defects. Four individuals with aortic root dilatation have been reported, with one adult individual experiencing progressive aortic dilation and dissection at age 38 years. Additionally, one individual with rib osteosarcoma and another with Wilms tumor have been reported (an overall prevalence of malignancy of about 2%). Therefore, MALNS appears to be in the same low risk group as Sotos syndrome and Weaver syndrome with respect to a low likelihood of developing cancer.
DIAGNOSIS/TESTING: The diagnosis of MALNS is established in a proband with suggestive findings and either a heterozygous pathogenic variant in (75% of affected individuals) OR a heterozygous deletion of 19p13.2 that includes (25% of affected individuals) identified by molecular genetic testing.
Feeding therapy with a low threshold for clinical feeding evaluation &/or radiographic swallowing study for those with clinical signs or symptoms of dysphagia; gastrostomy tube placement may be required for persistent feeding issues. Stool softeners, prokinetics, osmotic agents, or laxatives as needed for constipation. Symptomatic treatment for autonomic signs based on the underlying cause. Cognitive behavioral therapy (CBT) may be used to treat anxiety and ADHD. Symptomatic aids (i.e., colored glasses, low voice tone) may reduce anxiety outbursts. Hearing aids may be helpful per otolaryngologist. Standard treatment for epilepsy, Chari I malformation, developmental delay / intellectual disability, scoliosis/kyphosis, pes planus, pectus anomalies, refractive error, strabismus, tooth anomalies / malocclusion, aortic root dilatation / valvular issues, and cryptorchidism. At each visit, measure growth parameters and evaluate nutritional status and safety of oral intake; monitor for signs/symptoms of constipation, Chari I malformation, and subtle and nonspecific neurovegetative findings; and assess for new manifestations, such as seizures and changes in tone. The first BMI evaluation should be performed after age two years; assess caloric intake and BMI every six months during the first two years of life, then at least annually. Monitor developmental progress, educational needs, and psychopathologic symptoms annually from age 12 months to age 36 months and then approximately every two years from age three to six years. Annual ophthalmology evaluation until puberty and then periodically in adults to evaluate for late-onset optic nerve degeneration. Annual audiology evaluation in childhood or as clinically indicated. At least annual routine dental/orthodontic evaluation. Consider DXA scan for bone mineral density periodically in those with a history of multiple fractures or previous low bone mineral density. If the baseline cardiovascular evaluation is normal, consider annual cardiology follow up; limited data on aortic root progression is available for adults. No tumor screening protocols have been proposed or recommended for individuals with MALNS.
MALNS is an autosomal dominant disorder typically caused by a genetic alteration. Therefore, the risk to other family members is presumed to be low. Rarely, individuals diagnosed with MALNS have the disorder as the result of a genetic alteration inherited from a mosaic parent. Families with sib recurrence due to parental gonadal (or somatic and gonadal) mosaicism have been reported. Once an pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.
马兰综合征(MALNS)的特征包括产前和产后过度生长、巨头畸形、骨龄超前和/或骨骼异常(脊柱侧弯、扁平足)、体型消瘦、发育迟缓/智力残疾(通常为中度至重度)、行为问题(包括特定的焦虑型和注意力缺陷多动障碍[ADHD])以及眼部表现(最常见的是斜视、屈光不正和蓝色巩膜)。受影响个体通常具有独特的面部特征,包括长而呈三角形的脸、前额发际线高且额头突出、鼻梁凹陷、眼窝深陷、睑裂向下倾斜、鼻子短且鼻孔前倾、鼻尖上翘、人中长、嘴巴小且常张开、上唇唇红薄、下唇外翻以及下巴突出。其他表现可能包括自主神经症状(发作性共济失调伴头晕和恶心和/或体位性晕厥)、癫痫发作或脑电图异常、肌张力低下、牙齿异常、长骨骨折以及(罕见)先天性心脏缺陷。已报告4例主动脉根部扩张患者,其中1例成年患者在38岁时出现进行性主动脉扩张和夹层。此外,还报告了1例肋骨骨肉瘤患者和1例肾母细胞瘤患者(总体恶性肿瘤患病率约为2%)。因此,就患癌可能性较低而言,MALNS似乎与索托斯综合征和韦弗综合征处于同一低风险组。
诊断/检测:MALNS的诊断基于先证者的提示性发现以及通过分子遗传学检测确定的杂合致病性变异(约75%的受影响个体)或19p13.2杂合缺失,该缺失包含(约25%的受影响个体)。
对于有吞咽困难临床体征或症状的患者,进行低阈值的临床喂养评估和/或放射学吞咽研究的喂养治疗;对于持续存在的喂养问题,可能需要放置胃造瘘管。根据需要使用大便软化剂、促动力药、渗透剂或泻药治疗便秘。根据潜在病因对自主神经症状进行对症治疗。认知行为疗法(CBT)可用于治疗焦虑和ADHD。对症辅助措施(如有色眼镜、低声调)可能会减少焦虑发作。根据耳鼻喉科医生的建议,助听器可能会有帮助。对癫痫、Chiari I畸形、发育迟缓/智力残疾、脊柱侧弯/后凸、扁平足、胸壁畸形、屈光不正、斜视、牙齿异常/错颌、主动脉根部扩张/瓣膜问题以及隐睾症进行标准治疗。每次就诊时,测量生长参数并评估营养状况和口服摄入的安全性;监测便秘、Chiari I畸形以及细微和非特异性神经植物性表现的体征/症状;并评估新出现的表现,如癫痫发作和肌张力变化。首次BMI评估应在2岁后进行;在生命的前两年,每六个月评估一次热量摄入和BMI,之后至少每年评估一次。从12个月至36个月每年监测发育进展、教育需求和心理病理症状,然后从3岁至6岁大约每两年监测一次。青春期前每年进行眼科评估,成人期则定期评估,以评估迟发性视神经变性。儿童期或根据临床指征进行年度听力评估。至少每年进行一次常规牙科/正畸评估。对于有多次骨折病史或既往骨密度低的患者,定期考虑进行双能X线吸收法(DXA)扫描以评估骨密度。如果基线心血管评估正常,考虑每年进行心脏科随访;关于成人主动脉根部进展的有限数据可用。尚未为MALNS患者提出或推荐肿瘤筛查方案。
MALNS是一种常染色体显性疾病,通常由基因改变引起。因此,推测其他家庭成员的风险较低。很少有被诊断为MALNS的个体是由于从嵌合型父母遗传的基因改变而患病。已报告因父母性腺(或体细胞和性腺)嵌合导致同胞复发的家庭。一旦在受影响家庭成员中鉴定出致病性变异,就可以进行产前和植入前基因检测。